Description
ML 385 is a novel and specific inhibitor of nuclear factor erythroid 2-related factor 2 (Nrf2; IC50 = 1.9 µM). ML 385 blocks NRF2 transcriptional activity, and enhances the efficacy of carboplatin as well as other chemotherapeutic drugs in lung cancer cells (NSCLC)